Jim Simons Kazia Therapeutics LTD Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$6.05 - $8.65 $135,671 - $193,976	-22,425 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$7.35 - $12.0 $18,742 - $30,600	-2,550 Reduced 10.21%	22,425 $189,000
Q3 2021 Nov 12, 2021	SELL	$8.65 - $11.64 $353,335 - $475,470	-40,848 Reduced 62.06%	24,975 $283,000
Q2 2021 Aug 13, 2021	BUY	$9.1 - $14.71 $391,145 - $632,279	42,983 Added 188.19%	65,823 $649,000
Q1 2021 May 13, 2021	SELL	$8.98 - $12.86 $509,929 - $730,255	-56,785 Reduced 71.32%	22,840 $283,000
Q4 2020 Feb 10, 2021	BUY	$5.61 - $13.47 $11,781 - $28,287	2,100 Added 2.71%	79,625 $688,000
Q3 2020 Nov 13, 2020	BUY	$3.33 - $8.26 $38,158 - $94,651	11,459 Added 17.34%	77,525 $523,000
Q2 2020 Aug 13, 2020	BUY	$2.56 - $3.6 $81,512 - $114,627	31,841 Added 93.03%	66,066 $224,000
Q1 2020 May 14, 2020	SELL	$2.72 - $4.64 $4,436 - $7,567	-1,631 Reduced 4.55%	34,225 $99,000
Q4 2019 Feb 13, 2020	BUY	$2.84 - $7.4 $4,348 - $11,329	1,531 Added 4.46%	35,856 $156,000
Q4 2018 Feb 13, 2019	BUY	$2.2 - $3.18 $75,515 - $109,153	34,325 New	34,325 $83,000

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $87.5M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.